AR072353A1 - Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasa - Google Patents
Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasaInfo
- Publication number
- AR072353A1 AR072353A1 ARP090101295A ARP090101295A AR072353A1 AR 072353 A1 AR072353 A1 AR 072353A1 AR P090101295 A ARP090101295 A AR P090101295A AR P090101295 A ARP090101295 A AR P090101295A AR 072353 A1 AR072353 A1 AR 072353A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nhc
- substituted
- phenyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Ese tipo de compuestos puede utilizarse en composiciones farmacéuticas y métodos para la modulacion de LTA4H y para el tratamiento de estados de enfermedad, trastornos y afecciones mediados por la actividad de LTA4H hidrolasa, como inflamacion. Reivindicacion 1: Una entidad química seleccionada entre los compuestos de formula (1), las sales aceptables para uso farmacéutico de los compuestos de formula (1), los profármacos aceptables para uso farmacéutico de los compuestos de formula (1), y los solvatos de los compuestos de formula (1), donde X4, X5, X6 y X7 se definen como uno de los siguientes (a) y (b): a) uno de X4, X5, X6 y X7 es N y los otros son CRa; donde cada Ra es independientemente H, metilo, cloro, fluor o trifluorometilo; b) cada uno de X4 y X7 es N y cada uno de X5 y X6 es CH; cada uno de R1 y R2 es independientemente H, -(CH2)2-3OCH3, -CH2C(O)NH2, -(CH2)3NH2, -(CH2)1-2CO2H, -CH2CO2CH2CH3, bencilo, 3-(2-oxo-pirrolidin-1-il)-propilo, 1-acetil-azetidin-3-ilmetilo, cicloalquilo monocíclico, 1-metil-4-piperidinilo, o alquilo C1-4 no sustituido o sustituido con fenilo, cicloalquilo monocíclico, OH o NRbRc; donde Rb y Rc son cada uno independientemente H, -C(O)CH3 o alquilo C1-4, o Rb y Rc tomados en forma conjunta con el nitrogeno al cual están unidos forman un anillo de heterocicloalquilo monocíclico saturado; o R1 y R2 tomados en forma conjunta con el nitrogeno al cual están unidos forman i) un anillo heterocicloalquilo monocíclico saturado, opcionalmente fusionado a un anillo fenilo, y no sustituido o sustituido con uno o dos sustituyentes Rd; donde cada sustituyente Rd es independientemente alquilo C1-4 no sustituido o sustituido con -OH; -OH; =O; -(CH2)0-2N(CH3)2; -CF3; halo; -CO2-alquilo C1-4; -(CH2)0-2CO2H; -C(O)NH2; fenilo; bencilo; morfolin-4-ilo; piridilo; pirimidinilo; 1-piperidilo; fenoxi; 2-oxo-pirrolidin-1-ilo; 4-hidroxi-2-oxo-pirrolidin-1-ilo; -C(O)NRf-alquilo C1-4; -C(O)NHC(CH3)2CH2OH; -O-piridinilo; -O-pirimidinilo; -S-fenilo; (4-metilfenil)-sulfanilo; -S-piridinilo; -C(O)-alquilo C1-4; -C(O)-cicloalquilo monocíclico saturado; -C(O)-(CH2)0-1-2-tiofen-ilo; -C(O)-2-furanilo; -C(O)-4-morfolinilo; -C(O)-piridilo; -C(O)-1-pirrolidinilo; -C(O)-fenilo opcionalmente sustituido con un cloro; -C(O)-1-piperazinilo opcionalmente sustituido con alquilo C1-4; -(CH2)0-1-NHC(O)-alquilo C1-4; -NHC(O)-cicloalquilo monocíclico saturado; -NHS(O)(O)CH3; -NHC(O)-CH2OCH3; -NHC(O)-piridinilo; o -NHC(O)-2-tiofen-ilo, donde cada fenilo en Rd está no sustituido o sustituido con -CF3, halo o metoxi; o ii) una de las porciones del grupo de formulas (2), donde Re es alquilo C1-4, -C(O)-alquilo C1-4, -SO2CH3, -C(O)CH2NH2 o -C(O)NH2; Rf es H o -CH3; y A es -CH2-, -CH2CH2- o -OCH2CH2-.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4434908P | 2008-04-11 | 2008-04-11 | |
| US14912909P | 2009-02-02 | 2009-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072353A1 true AR072353A1 (es) | 2010-08-25 |
Family
ID=41130551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101295A AR072353A1 (es) | 2008-04-11 | 2009-04-13 | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasa |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US7939527B2 (es) |
| EP (2) | EP2268646B9 (es) |
| JP (2) | JP5530423B2 (es) |
| KR (1) | KR101228378B1 (es) |
| CN (1) | CN102056933B (es) |
| AR (1) | AR072353A1 (es) |
| AU (1) | AU2009234140B2 (es) |
| BR (1) | BRPI0911336A2 (es) |
| CA (1) | CA2721099C (es) |
| CL (1) | CL2009000877A1 (es) |
| CO (1) | CO6260069A2 (es) |
| CY (1) | CY1114628T1 (es) |
| DK (2) | DK2268646T3 (es) |
| EA (1) | EA018802B1 (es) |
| EC (1) | ECSP10010558A (es) |
| ES (2) | ES2400875T3 (es) |
| HK (2) | HK1152041A1 (es) |
| HN (1) | HN2010002074A (es) |
| HR (2) | HRP20130278T1 (es) |
| IL (2) | IL208480A (es) |
| JO (1) | JO2911B1 (es) |
| MX (1) | MX2010011154A (es) |
| MY (1) | MY157597A (es) |
| NI (1) | NI201000168A (es) |
| NZ (2) | NZ599853A (es) |
| PE (1) | PE20091779A1 (es) |
| PH (1) | PH12013500094A1 (es) |
| PL (2) | PL2336125T3 (es) |
| PT (2) | PT2268646E (es) |
| RS (2) | RS52712B (es) |
| SI (2) | SI2268646T1 (es) |
| SV (1) | SV2010003694A (es) |
| TW (2) | TWI461196B (es) |
| UY (1) | UY31760A (es) |
| WO (1) | WO2009126806A2 (es) |
| ZA (1) | ZA201008054B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| RS52712B (en) * | 2008-04-11 | 2013-08-30 | Janssen Pharmaceutica N.V. | THIAZOLOPYRIDIN-2-ILOXY-PHENYL I THIAZOLOPYRZIN-2-ILOXY-PHENYL KAO MODULATOR FOR LEUKOTRIEN A4 HYDROLAZE |
| AR091315A1 (es) * | 2012-03-06 | 2015-01-28 | Boehringer Ingelheim Int | Inhibidores de benzodioxano de la produccion de leucotrieno |
| KR20140138851A (ko) | 2012-03-06 | 2014-12-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 류코트리엔 생성 억제를 위해 기타 활성제와 병용된 벤조디옥산 |
| TW201416354A (zh) | 2012-07-17 | 2014-05-01 | Boehringer Ingelheim Int | 白三烯生成抑制劑 |
| EP2746260A1 (en) | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
| EP2746259A1 (en) | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
| AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| CA2906086A1 (en) * | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| CA3102077A1 (en) | 2018-05-31 | 2019-12-05 | Sanjeev AHUJA | Method of reducing pulmonary exacerbations in respiratory disease patients |
| BR112021013637A2 (pt) | 2019-01-11 | 2021-09-14 | Naegis Pharmaceuticals Inc. | Inibidores da síntese de leucotrieno |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008A (en) * | 1847-03-13 | Machinery for cleaning | ||
| IL59004A0 (en) | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
| US4321378A (en) | 1979-01-16 | 1982-03-23 | Delalande S.A. | 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives |
| FR2446823A1 (fr) | 1979-01-16 | 1980-08-14 | Delalande Sa | Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique |
| FR2476088A2 (fr) | 1979-01-16 | 1981-08-21 | Delalande Sa | Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique |
| US4329466A (en) | 1979-01-16 | 1982-05-11 | Delalande S.A. | Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives |
| US4424358A (en) | 1979-01-16 | 1984-01-03 | Delalande S.A. | β-3-Amino nor-tropane compounds |
| US4352802A (en) | 1980-06-10 | 1982-10-05 | Beecham Group Limited | Bicyclo[3.3.1]nonyl-benzamide |
| NZ199080A (en) | 1980-12-12 | 1984-07-31 | Beecham Group Ltd | 2-alkoxy-4-amino-5-alkylsulphonyl-n-(3beta-(8-hydrocarbyl-8-azabicyclo (3,2,1)octyl))benzamides |
| US4432983A (en) | 1981-04-30 | 1984-02-21 | Research Corporation | Conformationally restricted histamine H2 -receptor antagonists containing a tropane ring |
| DE3137996A1 (de) * | 1981-09-24 | 1983-04-28 | Hoechst Ag, 6230 Frankfurt | Heterocyclische phenylaether, verfahren zu deren herstellung und diese enthaltende herbizide mittel |
| US4571396A (en) * | 1984-04-16 | 1986-02-18 | Warner-Lambert Company | Antibacterial agents |
| US4873346A (en) * | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
| NZ222047A (en) | 1986-10-08 | 1991-01-29 | Bristol Myers Co | Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents |
| DK171349B1 (da) * | 1986-11-14 | 1996-09-16 | Hoffmann La Roche | Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler |
| JPS63170356A (ja) | 1986-12-30 | 1988-07-14 | Yamanouchi Pharmaceut Co Ltd | アニリン誘導体及びその製造法 |
| FI91859C (fi) * | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| US5070094A (en) | 1989-09-05 | 1991-12-03 | G. D. Searle & Co. | N-benzyltropaneamides |
| US5220063A (en) * | 1991-05-10 | 1993-06-15 | Hoechst Celanese Corporation | Method for the preparation of arylalkanolacylamides |
| US5296486A (en) * | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
| US5472964A (en) * | 1992-12-22 | 1995-12-05 | Merck Frosst Canada, Inc. | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists |
| TW251287B (es) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| US5585492A (en) | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| US6506876B1 (en) * | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| US6632976B1 (en) * | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
| WO1997029774A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| US6110994A (en) * | 1996-06-14 | 2000-08-29 | Cabot Corporation | Polymeric products containing modified carbon products and methods of making and using the same |
| US6110944A (en) | 1997-03-12 | 2000-08-29 | G. D. Searle & Co. | LTA4, hydrolase inhibitors |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| US6432976B1 (en) | 1999-10-29 | 2002-08-13 | Merck & Co., Inc. | 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
| US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| FR2831884B1 (fr) | 2001-11-02 | 2003-12-26 | Pf Medicament | Nouveaux derives amides heteroaromatiques de 3 beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique |
| EP1367481A3 (en) * | 2002-05-29 | 2008-04-09 | Hitachi, Ltd. | Centralized storage management method |
| US7329682B2 (en) * | 2003-04-03 | 2008-02-12 | Ewha University-Industry Collaboration Foundation | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| AU2004247627A1 (en) | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
| CA2534212A1 (en) * | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica, N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| US7825109B2 (en) * | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| US7435831B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| CN101005838A (zh) | 2004-06-22 | 2007-07-25 | 先灵公司 | 大麻素受体配体 |
| GB2415818B (en) | 2004-06-30 | 2008-12-31 | Autoliv Dev | Arrangement for triggering a vehicle safety device |
| AU2005283326B2 (en) | 2004-09-13 | 2011-07-21 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| AU2006230379A1 (en) * | 2005-03-31 | 2006-10-05 | Janssen Pharmaceutica N.V. | Phenyl and pyridyl LTA4H modulators |
| ES2277745B1 (es) | 2005-06-14 | 2008-06-01 | Laboratorios Almirall S.A. | Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1. |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
| JP5363315B2 (ja) | 2006-06-06 | 2013-12-11 | コーナーストーン セラピューティクス インコーポレイテッド | 新規ピペラジン、医薬組成物、およびその使用方法 |
| WO2008016811A2 (en) | 2006-07-31 | 2008-02-07 | Neurogen Corporation | Aminopiperidines and realted compounds |
| AU2007333667A1 (en) * | 2006-12-19 | 2008-06-26 | Auspex Pharmaceuticals, Inc. | Preperation and utility of CCR5 inhibitors |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| PA8802501A1 (es) * | 2007-10-31 | 2009-06-23 | Janssen Pharmaceutica Nv | Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa |
| RS52712B (en) * | 2008-04-11 | 2013-08-30 | Janssen Pharmaceutica N.V. | THIAZOLOPYRIDIN-2-ILOXY-PHENYL I THIAZOLOPYRZIN-2-ILOXY-PHENYL KAO MODULATOR FOR LEUKOTRIEN A4 HYDROLAZE |
-
2009
- 2009-04-09 RS RS20130120A patent/RS52712B/en unknown
- 2009-04-09 WO PCT/US2009/040070 patent/WO2009126806A2/en active Application Filing
- 2009-04-09 KR KR1020107025118A patent/KR101228378B1/ko active IP Right Grant
- 2009-04-09 PL PL11159236T patent/PL2336125T3/pl unknown
- 2009-04-09 US US12/421,406 patent/US7939527B2/en active Active
- 2009-04-09 PL PL09729596T patent/PL2268646T3/pl unknown
- 2009-04-09 ES ES11159236T patent/ES2400875T3/es active Active
- 2009-04-09 DK DK09729596.8T patent/DK2268646T3/da active
- 2009-04-09 NZ NZ599853A patent/NZ599853A/xx not_active IP Right Cessation
- 2009-04-09 MY MYPI2010004692A patent/MY157597A/en unknown
- 2009-04-09 CA CA2721099A patent/CA2721099C/en not_active Expired - Fee Related
- 2009-04-09 RS RS20130527A patent/RS53081B/en unknown
- 2009-04-09 ES ES09729596.8T patent/ES2440746T3/es active Active
- 2009-04-09 EP EP09729596.8A patent/EP2268646B9/en active Active
- 2009-04-09 SI SI200930743T patent/SI2268646T1/sl unknown
- 2009-04-09 EP EP11159236A patent/EP2336125B1/en active Active
- 2009-04-09 AU AU2009234140A patent/AU2009234140B2/en not_active Ceased
- 2009-04-09 JP JP2011504176A patent/JP5530423B2/ja not_active Expired - Fee Related
- 2009-04-09 EA EA201071186A patent/EA018802B1/ru unknown
- 2009-04-09 NZ NZ588341A patent/NZ588341A/en not_active IP Right Cessation
- 2009-04-09 SI SI200930535T patent/SI2336125T1/sl unknown
- 2009-04-09 CL CL2009000877A patent/CL2009000877A1/es unknown
- 2009-04-09 BR BRPI0911336-3A patent/BRPI0911336A2/pt not_active Application Discontinuation
- 2009-04-09 PT PT97295968T patent/PT2268646E/pt unknown
- 2009-04-09 CN CN200980122416.8A patent/CN102056933B/zh not_active Expired - Fee Related
- 2009-04-09 JO JO2009128A patent/JO2911B1/en active
- 2009-04-09 MX MX2010011154A patent/MX2010011154A/es active IP Right Grant
- 2009-04-09 PT PT111592366T patent/PT2336125E/pt unknown
- 2009-04-09 DK DK11159236.6T patent/DK2336125T3/da active
- 2009-04-10 TW TW098111909A patent/TWI461196B/zh not_active IP Right Cessation
- 2009-04-10 TW TW103104197A patent/TW201420100A/zh unknown
- 2009-04-13 AR ARP090101295A patent/AR072353A1/es unknown
- 2009-04-13 UY UY0001031760A patent/UY31760A/es unknown
- 2009-04-13 PE PE2009000508A patent/PE20091779A1/es active IP Right Grant
-
2010
- 2010-10-05 IL IL208480A patent/IL208480A/en active IP Right Grant
- 2010-10-11 HN HN2010002074A patent/HN2010002074A/es unknown
- 2010-10-11 SV SV2010003694A patent/SV2010003694A/es unknown
- 2010-10-11 NI NI201000168A patent/NI201000168A/es unknown
- 2010-10-20 EC EC2010010558A patent/ECSP10010558A/es unknown
- 2010-10-22 CO CO10131314A patent/CO6260069A2/es active IP Right Grant
- 2010-11-10 ZA ZA2010/08054A patent/ZA201008054B/en unknown
-
2011
- 2011-03-02 US US13/039,105 patent/US20110190503A1/en not_active Abandoned
- 2011-03-02 US US13/039,017 patent/US8357684B2/en not_active Expired - Fee Related
- 2011-06-16 HK HK11106213.5A patent/HK1152041A1/xx not_active IP Right Cessation
- 2011-11-24 HK HK11112776.2A patent/HK1158208A1/xx not_active IP Right Cessation
-
2013
- 2013-01-14 PH PH12013500094A patent/PH12013500094A1/en unknown
- 2013-03-27 HR HRP20130278AT patent/HRP20130278T1/hr unknown
- 2013-05-09 IL IL226244A patent/IL226244A/en active IP Right Grant
- 2013-11-20 CY CY20131101029T patent/CY1114628T1/el unknown
- 2013-12-16 HR HRP20131192AT patent/HRP20131192T1/hr unknown
- 2013-12-25 JP JP2013266767A patent/JP5675943B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072353A1 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasa | |
| AR061761A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| CL2020002866A1 (es) | Compuestos de heteroaril tetracíclicos | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR106755A2 (es) | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos | |
| AR083543A1 (es) | Diamidas de amino-pirrolidin-azetidinas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar dolores inflamatorios | |
| HRP20160253T1 (hr) | Inhibitor benzodiazepinske bromodomene | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| AR069777A1 (es) | Moduladores imidazolo-, oxazolo-, tiazolopirimidina del trpv1 | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| DOP2016000045A (es) | Compuestos de benzoxaborol tricíclicos y usos de los mismos | |
| AR075594A1 (es) | Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4 | |
| AR074184A1 (es) | Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| AR069400A1 (es) | 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios | |
| AR066421A1 (es) | Compuestos derivados de piridona | |
| AR055744A1 (es) | Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos | |
| AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| CL2017002060A1 (es) | Compuestos de benzoxaborol y usos de los mismos | |
| AR040332A1 (es) | Derivados de acido benzoico como moduladores de ppar alfa y gamma | |
| AR052549A1 (es) | Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2 | |
| AR077301A1 (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |